Table 12.
Univariate and multi-variate models assessing the impact of the COVID-19 pandemic on HIV testing rates among people hospitalised for an injecting-related hospital admission (IRHA) in Glasgow city, 2010–2021 (June 2021 only)
| Co-variates | N | HIV test in the last year (% of N) | Univariateb | Multi-variateb | ||
|---|---|---|---|---|---|---|
| OR (95% CI) | P value | aOR (95% CI) | P value | |||
| Time perioda | ||||||
| Pre-outbreak (2010–2014) | 3,056 | 557 (18%) | 0.24 (0.21–0.30) | < 0.001 | 0.18 (0.16–0.20) | < 0.001 |
| Early outbreak (2015–2016) | 2,149 | 807 (38%) | 0.65 (0.58–0.72) | < 0.001 | 0.52 (0.46–0.58) | < 0.001 |
| Ongoing outbreak (2017–2019) | 3,474 | 1,671 (48%) | 1 | 1 | ||
| COVID-19 (2020–2021) | 2,082 | 1,055 (51%) | 1.11 (1.00–1.23) | 0.049 | 1.11 (0.98–1.24) | 0.080 |
| Gender | ||||||
| Male | 5,848 | 2,315 (39%) | 1 | 1 | ||
| Female | 2,259 | 882 (39%) | 0.99 (0.90–1.09) | 0.870 | 0.97 (0.87–1.07) | 0.650 |
| Age groupa | ||||||
| < 35 | 3,636 | 902 (25%) | 1 | 1 | ||
| 35–45 | 3,677 | 1,703 (46%) | 2.61 (2.35–2.90) | < 0.001 | 1.37 (1.22–1.55) | < 0.001 |
| 46 + | 3,448 | 1,485 (43%) | 2.29 (2.06–2.55) | < 0.001 | 0.98 (0.87–1.11) | 0.780 |
| Methadone prescribinga | ||||||
| Not prescribed | 4,506 | 841 (19%) | 1 | 1 | ||
| In the last 6 months | 5,251 | 2,768 (53%) | 4.86 (4.41–5.35) | < 0.001 | 5.63 (5.01–6.32) | < 0.001 |
| In the past but not the last 6 months | 1,004 | 481 (48%) | 4.01 (3.45–4.65) | < 0.001 | 4.40 (3.72–5.21) | < 0.001 |
OR odds ratio, aOR adjusted odds ratio
aTime varying co-variate; people can be included in multiple categories
bMulti-level framework to adjust for across time period duplicates